探究诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效.docVIP

探究诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效 　　【摘要】目的探究与分析诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效。方法选取本院自2012年12月~2013年11月收治的初诊重度2型糖尿病患者60例, 将其作为临床研究对象, 采取随机数字表法分为对照组和观察组, 每组各30例, 对照组给予诺和锐30治疗, 观察组在其基础上加用维格列汀治疗, 观察与对比两组患者的临床疗效。结果两组患者治疗后空腹血糖、餐后血糖、HbA1c、甘油三酯、总胆固醇、低密度脂蛋白胆固醇较治疗前显著降低, 差异有统计学意义(P0.05), 观察组较对照组降低显著, P0.05, 差异具有统计学意义。结论诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效显著, 能够全面降低患者血糖, 不良反应少, 低血糖发生率低。 　　【关键词】诺和锐30；维格列汀；初诊重度2型糖尿病；疗效 　　 　　Clinical effect of aspart 30 combined with vildagliptin in the treatment of newly diagnosed type 2 diabetesYU Min-min, YANG Wei-fang. Qingdao Municipal Hospital, Qingdao 266071, China 　　【Abstract】Objective To explore and analyze clinical effect of aspart 30 combined with vildagliptin in the treatment of newly diagnosed severe type 2 diabetes. Methods From December 2012 to November 2013, 60 cases of newly diagnosed severe type 2 diabetic patients were randomly divided into control group and observation group, 30 cases for each group, control group were given aspart treatment, observation group received vildagliptin treatment on its basis, and clinical efficacy of two groups was compared. Results After treatment, levels of fasting plasma glucose, postprandial glucose, HbA1c, TG, TC and LDL-C in observation group decreased significantly compared with control group, P0.05, statistically significant. Conclusion Aspart 30 combined with vildagliptin therapy can significantly decrease blood sugar of newly severe diagnosed type 2 diabetes with less adverse reaction and low rates of hypoglycemia. 　　【Key words】Aspart 30; Vildagliptin; Newly diagnosed severe type 2 diabetes; Effect近年来我国新诊断2型糖尿病的发病率显著增加, 初诊HbA1c超过9%的患者比例达28.8%。AACE指南中认为, 对这类患者即可给予胰岛素治疗。糖尿病治疗的最终目标是减少糖尿病并发症和改善患者预后。肠促胰素为基础的治疗是当今2型糖尿病治疗领域中的一大进展。维格列汀是一种高选择性DPP-4抑制剂, 对α、β细胞具有双向调节作用。本研究对初诊严重高血糖患者在应用诺和锐30的基础上, 联合维格列汀治疗。现将研究结果报告如下。 　　1资料与方法 　　1. 1一般资料选取本院自2012年12月~2013年11月收治的2型糖尿病患者60例。入选标准：均符合1999年WHO提出的2型糖尿病诊断标准和分型；初诊2型糖尿病患者经饮食控制后, 空腹血糖11.1 mmol/L或餐后血糖15.0 mmol/L；年龄18~70岁。排除标准：孕妇、哺乳期；严重感染；存在糖尿病急性并发症；肿瘤；心肺功能不全；肝肾功能损害；